Phenotypic reversion of invasive neurofibromin-deficient schwannoma by FTS: Ras inhibition reduces BMP4/Erk/Smad signaling

Molecular Cancer Therapeutics

Volumn 10, Issue 8, 2011, Pages 1317-1326

  Barkan, Batya ^a   Kloog, Yoel ^a   Ehrlich, Marcelo ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; BONE MORPHOGENETIC PROTEIN 4; CLATHRIN; FOCAL ADHESION KINASE; GELATINASE; GELATINASE A; GELATINASE B; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; NEUROFIBROMIN; NOGGIN; RAC PROTEIN; RAS PROTEIN; SALIRASIB; SMAD PROTEIN; SMAD1 PROTEIN; SMAD3 PROTEIN; SMAD5 PROTEIN; SMAD8 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CANCER CELL CULTURE; CELL ADHESION; CELL MOTILITY; CELL SPREADING; CELL STRUCTURE; CONTROLLED STUDY; ENZYME RELEASE; EXTRACELLULAR MATRIX; GENE EXPRESSION; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; MITOGENESIS; NERVE SHEATH TUMOR; NEURILEMOMA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FAMILY; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; BONE MORPHOGENETIC PROTEIN 4; CELL LINE, TUMOR; CELL MOVEMENT; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FARNESOL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MODELS, BIOLOGICAL; NEURILEMMOMA; NEUROFIBROMIN 1; PHENOTYPE; RAS PROTEINS; SALICYLIC ACIDS; SIGNAL TRANSDUCTION; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA;

EID: 80051587695     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-1087     Document Type: Article

References (47)

1. Vicente-Duenas C, Gutierrez de Diego J, Rodriguez FD, Jimenez R, Cobaleda C. The role of cellular plasticity in cancer development. Curr Med Chem 2009;16:3676-85.
2. DeNicola GM, Tuveson DA. RAS in cellular transformation and senescence. Eur J Cancer 2009;45 Suppl 1:211-6.
3. Miyazono K. Transforming growth factor-beta signaling in epithelial-mesenchymal transition and progression of cancer. Proc Jpn Acad Ser B Phys Biol Sci 2009;85:314-23.
4. Bailey JM, Singh PK, Hollingsworth MA. Cancer metastasis facilitated by developmental pathways: Sonic hedgehog, Notch, and bone morphogenic proteins. J Cell Biochem 2007;102:829-39. (Pubitemid 350036923)
5. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial- mesenchymal transitions. Nat Rev Mol Cell Biol 2006;7:131-42. (Pubitemid 43278296)
6. Sela-Donenfeld D, Kalcheim C. Regulation of the onset of neural crest migration by coordinated activity of BMP4 and Noggin in the dorsal neural tube. Development 1999;126:4749-62.
7. Deng H, Makizumi R, Ravikumar TS, Dong H, Yang W, Yang WL. Bone morphogenetic protein-4 is overexpressed in colonic adenocarcinomas and promotes migration and invasion of HCT116 cells. Exp Cell Res 2007;313:1033-44. (Pubitemid 46273448)
8. Theriault BL, Shepherd TG, Mujoomdar ML, Nachtigal MW. BMP4 induces EMT and Rho GTPase activation in human ovarian cancer cells. Carcinogenesis 2007;28:1153-62. (Pubitemid 47062673)
9. Gotzmann J, Mikula M, Eger A, Schulte-Hermann R, Foisner R, Beug H, et al. Molecular aspects of epithelial cell plasticity: implications for local tumor invasion and metastasis. Mutat Res 2004;566:9-20. (Pubitemid 38045586)
10. Mulder KM. Role of Ras and Mapks in TGFbeta signaling. Cytokine Growth Factor Rev 2000;11:23-35. (Pubitemid 30169723)
11. Kfir S, Ehrlich M, Goldshmid A, Liu X, Kloog Y, Henis YI. Pathway- and expression level-dependent effects of oncogenic N-Ras: p27(Kip1) mislocalization by the Ral-GEF pathway and Erk-mediated interference with Smad signaling. Mol Cell Biol 2005;25:8239-50. (Pubitemid 41263014)
12. Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989;49:4682-9. (Pubitemid 19213607)
13. Stephens K, Riccardi VM, Rising M, Ng S, Green P, Collins FS, et al. Linkage studies with chromosome 17 DNA markers in 45 neurofibromatosis 1 families. Genomics 1987;1:353-7.
14. Hirota S, Nomura S, Asada H, Ito A, Morii E, Kitamura Y. Possible involvement of c-kit receptor and its ligand in increase of mast cells in neurofibroma tissues. Arch Pathol Lab Med 1993;117:996-9. (Pubitemid 23292026)
15. Ferner RE, Gutmann DH. International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Cancer Res 2002;62:1573-7. (Pubitemid 34407825)
16. Hiatt KK, Ingram DA, Zhang Y, Bollag G, Clapp DW. Neurofibromin GTPase-activating protein-related domains restore normal growth in Nf1-/- cells. J Biol Chem 2001;276:7240-5.
17. Cawthon RM, Weiss R, Xu GF, Viskochil D, Culver M, Stevens J, et al. A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations. Cell 1990;62:193-201.
18. Ballester R, Marchuk D, Boguski M, Saulino A, Letcher R, Wigler M, et al. The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins. Cell 1990;63:851-9. (Pubitemid 120035058)
19. Kloog Y, Cox AD. RAS inhibitors: potential for cancer therapeutics. Mol Med Today 2000;6:398-402.
20. Barkan B, Starinsky S, Friedman E, Stein R, Kloog Y. The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1. Clin Cancer Res 2006;12:5533-42. (Pubitemid 44497271)
21. Harrisingh MC, Perez-Nadales E, Parkinson DB, Malcolm DS, Mudge AW, Lloyd AC. The Ras/Raf/ERK signalling pathway drives Schwann cell dedifferentiation. EMBO J 2004;23:3061-71. (Pubitemid 39093600)
22. Yang FC, Chen S, Clegg T, Li X, Morgan T, Estwick SA, et al. Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling. Hum Mol Genet 2006;15:2421-37. (Pubitemid 44288696)
23. Benard V, Bohl BP, Bokoch GM. Characterization of rac and cdc42 activation in chemoattractant-stimulated human neutrophils using a novel assay for active GTPases. J Biol Chem 1999;274:13198-204.
24. Haklai R, Gana-Weisz G, Elad G, Paz A, Marciano D, Egozi Y, et al. Dislodgment and accelerated degradation of Ras. Biochemistry 1998;37:1306-14.
25. Rotblat B, Ehrlich M, Haklai R, Kloog Y. The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancer. Methods Enzymol 2008;439:467-89.
26. Shapira S, Barkan B, Fridman E, Kloog Y, Stein R. The tumor suppressor neurofibromin confers sensitivity to apoptosis by Ras-dependent and Ras-independent pathways. Cell Death Differ 2006.
27. Lambert JM, Lambert QT, Reuther GW, Malliri A, Siderovski DP, Sondek J, et al. Tiam1 mediates Ras activation of Rac by a PI(3)K-independent mechanism. Nat Cell Biol 2002;4:621-5.
28. Ingram DA, Hiatt K, King AJ, Fisher L, Shivakumar R, Derstine C, et al. Hyperactivation of p21(ras) and the hematopoietic-specific Rho GTPase, Rac2, cooperate to alter the proliferation of neurofibromin-deficient mast cells in vivo and in vitro. J Exp Med 2001;194:57-69. (Pubitemid 32660437)
29. Tomar A, Schlaepfer DD. Focal adhesion kinase: switching between GAPs and GEFs in the regulation of cell motility. Curr Opin Cell Biol 2009;21:676-83.
30. Boyanapalli M, Lahoud OB, Messiaen L, Kim B, Anderle de Sylor MS, Duckett SJ, et al. Neurofibromin binds to caveolin-1 and regulates ras, FAK, and Akt. Biochem Biophys Res Commun 2006;340:1200-8. (Pubitemid 43083405)
31. Grove M, Komiyama NH, Nave KA, Grant SG, Sherman DL, Brophy PJ. FAK is required for axonal sorting by Schwann cells. J Cell Biol 2007;176:277-82. (Pubitemid 46184879)
32. Law SF, Estojak J, Wang B, Mysliwiec T, Kruh G, Golemis EA. Human enhancer of filamentation 1, a novel p130cas-like docking protein, associates with focal adhesion kinase and induces pseudohyphal growth in Saccharomyces cerevisiae. Mol Cell Biol 1996;16:3327-37.
33. O'Neill GM, Seo S, Serebriiskii IG, Lessin SR, Golemis EA. A new central scaffold for metastasis: parsing HEF1/Cas-L/NEDD9. Cancer Research 2007;67:8975-9. (Pubitemid 47535876)
34. ArrayExpress. Available from: http://www.ebi.ac.uk/microarray-as/ae/.
35. DAVID functional annotation bioinformatics microarray analysis [internet]: DAVID bioinformatics resources 6.7, National Institute of Allergy and Infectious Diseases (NIAID), NIH. Available from: http://david.abcc.ncifcrf. gov/.
36. Chen S, Zhang Q, Wu X, Schultz PG, Ding S. Dedifferentiation of lineage-committed cells by a small molecule. J Am Chem Soc 2004;126:410-1. (Pubitemid 38084591)
37. Giehl K, Imamichi Y, Menke A. Smad4-independent TGF-beta signaling in tumor cell migration. Cells Tissues Organs 2007;185:123-30. (Pubitemid 46956853)
38. Liotta LA. Gene products which play a role in cancer invasion and metastasis. Breast Cancer Res Treat 1988;11:113-24.
39. Marshall CJ. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 1995;80:179-85.
40. Bodempudi V, Yamoutpoor F, Pan W, Dudek AZ, Esfandyari T, Piedra M, et al. Ral overactivation in malignant peripheral nerve sheath tumors. Mol Cell Biol 2009;29:3964-74.
41. Javelaud D, Mauviel A. Crosstalk mechanisms between the mitogen-activated protein kinase pathways and Smad signaling downstream of TGF-beta: implications for carcinogenesis. Oncogene 2005;24:5742-50. (Pubitemid 43086134)
42. Miyazono K, Maeda S, Imamura T. BMP receptor signaling: transcriptional targets, regulation of signals, and signaling cross-talk. Cytokine Growth Factor Rev 2005;16:251-63. (Pubitemid 40910315)
43. Beck SE, Carethers JM. BMP suppresses PTEN expression via RAS/ERK signaling. Cancer Biol Ther 2007;6:1313-7. (Pubitemid 351590388)
44. Janda E, Lehmann K, Killisch I, Jechlinger M, Herzig M, Downward J, et al. Ras and TGF[beta] cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways. J Cell Biol 2002;156:299-313. (Pubitemid 34839911)
45. Whyte J, Bergin O, Bianchi A, McNally S, Martin F. Key signalling nodes in mammary gland development and cancer. Mitogen-activated protein kinase signalling in experimental models of breast cancer progression and in mammary gland development. Breast Cancer Res 2009;11:209.
46. Mehler MF, Mabie PC, Zhang D, Kessler JA. Bone morphogenetic proteins in the nervous system. Trends Neurosci 1997;20:309-17. (Pubitemid 27348741)
47. Piccirillo SG, Reynolds BA, Zanetti N, Lamorte G, Binda E, Broggi G, et al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 2006;444:761-5. (Pubitemid 44949605)